New Delhi: Cadila Healthcare on Wednesday reported a 47.11 per cent rise in consolidated net profit at Rs 353.39 crore for the fiscal first quarter that ended on June 30, 2015, mainly on account of robust sales.
The drug firm had posted a net profit after taxes, minority interest and share of profit of associates of Rs 240.21 crore for the corresponding period a year ago, it said.
Consolidated total income from operations of the company rose to Rs 2,500.65 crore during the quarter under consideration as against Rs 2,050.12 crore in the year-ago period.
The company's formulations business in the US grew by 37 per cent during the quarter.
During the quarter, the group filed 6 additional ANDAs (abbreviated new drug applications) with the US Food and Drug Administration (FDA) and launched one new product in the US, Cadila Healthcare said.
In the Indian formulations market, the company said it launched 12 new products.
In a separate filing to the BSE, Cadila Healthcare said its board of directors has considered and approved the sub-division (split) of one equity share of the company having a face value of Rs 5 into five equity shares of face value of Rs 1 each.
Shares in Cadila Healthcare, on Tuesday, ended over 4 per cent higher at Rs 2003.50 apiece on the BSE.